MiR-492 as an Important Biomarker for Early Diagnosis and Targeted Treatment in Different Cancers

Author(s): Eskandar Taghizadeh, Forough Taheri, Daryoush Rostami, Pedram G. Renani, Gordon A. Ferns, Alireza Pasdar*, Majid G. Mobarhan*

Journal Name: Current Cancer Therapy Reviews

Volume 16 , Issue 4 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Recent studies have led to a more detailed understanding of the roles played by microRNAs in health and disease, and their potential use as biomarkers in physiological and pathophysiological processes involving cancer initiation and progression. MiR-492 is encoded by a pseudogene, has a key role in some human cancer cells and its overexpression in tissues, and it has been proposed that it can be used as a good biomarker for management and early diagnosis of some cancers including breast cancer, colorectal and ovarian cancer, hepatocellular cancer, retinoblastoma and pancreatic cancer. The aim of this review was to summarize the data of MiR-492 for early diagnosis and treatment of some types of related cancers.

Keywords: MiR-492, breast cancer, microRNAs, colorectal cancer, RNA-silencing, biomarker.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 20 November, 2020
Page: [269 - 275]
Pages: 7
DOI: 10.2174/1573394716666200309124048

Article Metrics

PDF: 14